J. Goldman & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

J. Goldman & Co’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.2M	Buy	215,945 +79,045	+58%	+$1.43M	0.11%	228
2026 Q1	$2.55M	Buy	136,900 +35,433	+35%	+$587K	0.07%	285
2025 Q4	$1.34M	Buy	+101,467	New	+$1.2M	0.04%	356
2025 Q2	–	Sell	-14,664	Closed	-$597K	–	569
2025 Q1	$573K	Buy	+14,664	New	+$632K	0.01%	399
2024 Q4	–	Sell	-16,162	Closed	-$815K	–	567
2024 Q3	$815K	Sell	16,162 -2,005	-11%	-$94K	0.02%	310
2024 Q2	$799K	Buy	18,167 +1,060	+6%	+$44.9K	0.02%	323
2024 Q1	$859K	Buy	+17,107	New	+$928K	0.03%	282

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Goldman & Co's MLTX Position: Q2 2026 in Review

J. Goldman & Co increased its MoonLake Immunotherapeutics (MLTX) stake by 58% in Q2 2026, buying an estimated $1.43M and bringing the position to 215,945 shares worth $4.2M. The position accounts for 0.11% of the portfolio, ranked #228.

J. Goldman & Co first reported a position in MLTX in Q1 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

J. Goldman & Co held 215,945 shares of MoonLake Immunotherapeutics worth $4.2M as of Q2 2026.
J. Goldman & Co bought 79,045 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.43M.
MoonLake Immunotherapeutics made up 0.11% of J. Goldman & Co's portfolio in Q2 2026, its #228 holding.
J. Goldman & Co first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 7 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.